🎁 Ihre Lieblingsaktie geschenkt. → Jetzt Depot bei SMARTBROKER+ eröffnen und Willkommensgeschenk sichern. 🎁 Ihre Lieblingsaktie geschenkt. → Jetzt Depot eröffnen

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Push-Kurse

NanoViricides Aktie

Aktie

ISIN: US6300873022 WKN: A2PSNF SYM: NV3P Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,3300

EUR

-5,67 %

-0,0800 EUR

Letzter Kurs 10.07.26 Tradegate

NanoViricides Aktie kaufen

Geldkurs

10.07.26

1,2900

EUR

390 STK

Briefkurs

10.07.26

1,3600

EUR

370 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Mo-Fr von 07:30 bis 23:00 Uhr
Neu: Samstag von 14:00 bis 19:00 Uhr

Nachrichten zu NanoViricides

Neueste Meldungen

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily Englische Nachricht

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo Englische Nachricht

Artikel in Nachrichten zu NanoViricides

Neueste
Meistgelesene

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher 29.06.26 · Accesswire
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo 15.06.26 · Accesswire

7 Tage
30 Tage
6 Monate

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo 06.07.26 · Accesswire · 156 Leser
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily 08.07.26 · Accesswire · 116 Leser

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo 15.06.26 · Accesswire · 160 Leser
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo 06.07.26 · Accesswire · 156 Leser
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher 29.06.26 · Accesswire · 132 Leser
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily 08.07.26 · Accesswire · 116 Leser

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies 08.06.26 · Accesswire · 232 Leser
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides 26.05.26 · Accesswire · 200 Leser
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II 15.05.26 · Accesswire · 184 Leser
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides 12.02.26 · Accesswire · 176 Leser
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 13.01.26 · Accesswire · 168 Leser
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides 01.04.26 · Accesswire · 164 Leser
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo 15.06.26 · Accesswire · 160 Leser
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo 06.07.26 · Accesswire · 156 Leser
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides 18.05.26 · Accesswire · 152 Leser
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete 11.03.26 · Accesswire · 152 Leser

NanoViricides News

NanoViricides News: Auf dieser Seite finden Sie alle NanoViricides News und Nachrichten zur NanoViricides Aktie. Dies beinhaltet die Agenturmeldungen auf wallstreet-online.de, aber auch NanoViricides News von einer Vielzahl an Gastautoren, Partnern und Analysten.